NEW YORK: The US government has agreed to pay $1.95 billion for 100 million doses of a potential COVID-19 vaccine jointly developed by Pfizer and BioNTech, the two companies said on Wednesday.
The doses of the vaccine, BNT162, will be obtained after Pfizer successfully manufactures and obtains approval or emergency use authorisation from the US Food and Drug Administration (FDA).
The US government can also acquire up to an additional 500 million doses, said US-based Pfizer and Germany-based BioNTech.
"Depending on the success in clinical trials, today's agreement will enable the delivery of approximately 100 million doses of this vaccine to the American people," Alex Azar, Secretary, US Department of Health and Human Services, said in a statement.
Americans will receive the vaccine for free, consistent with the US government's commitment for free access to COVID-19 vaccines.
"We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that the product would be available immediately if our clinical trials prove successful and an Emergency Use Authorisation is granted," Albert Bourla, Pfizer Chairman and CEO, said in a statement.
"We are honored to be a part of this effort to provide Americans access to protection from this deadly virus," the statement added.
The BNT162 programme is based on BioNTech's proprietary mRNA technology and is supported by Pfizer's global vaccine development and manufacturing capabilities.
The BNT162 vaccine candidates are undergoing clinical studies.
"We are also in advanced discussions with multiple other government bodies and we hope to announce additional supply agreements soon. Our goal remains to bring a safe and effective COVID-19 vaccine to many people around the world, as quickly as we can," said Ugur Sahin, CEO and Co-founder of BioNTech.
The Pfizer/BioNTech vaccine development programme is evaluating at least four experimental vaccines, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen. (IANS)
Also Watch: #NewsMakers: Youth sensation Ashish Chanchlani in an exclusive conversation with Oineetom Ojah: